Tag archive for ‘DiaPep277’
Globes On Tuesday, October 7th, 2014

Clal Biotech, Hyperion seek settlement over Andromeda

– Clal Biotechnology and Hyperion have agreed on an independent assessment of Andromeda’s Type 1 diabetes treatment. –   Clal Biotechnology (TASE: CBI), managed by Reuven Krupik, and More...

Globes On Tuesday, September 23rd, 2014

Clal Biotech Suing Hyperion for $200 Million over ‘Rash and Ill Considered’ Andromeda Decisions

Clal Biotechnology Industries Ltd. (TASE: CBI announced yesterday that it had filed a $200 million suit against drug company Hyperion Therapeutics Inc. (Nasdaq: HPTX) in the US in the State of Delaware Court, More...

Globes On Tuesday, September 9th, 2014

Hyperion Cancels Israeli Biotech Acquisition over Falsified Clinical Trial Results

By Gali Weinreb and Shiri Habib-Valdhorn Hyperion says it has “uncovered evidence” that Andromeda falsified clinical trial results. Hyperion Therapeutics Inc. (Nasdaq: HPTX) has cancelled its acquisition More...

Jewish Business News On Thursday, April 24th, 2014

Hyperion Therapeutics acquires Israeli Andromeda Biotech for up to $570 million

– Hyperion Therapeutics (Nasdaq:HPTX) announced today that it acquires Andromeda Biotech Ltd., an Israel-based subsidiary of Clal Biotechnology Industries Ltd. (TASE:CBI), for $20 million in cash More...

Koby Yeshayahou On Wednesday, February 26th, 2014

Clal Biotech Selling Diabetes Treatment Co Andromeda

– Clal Biotechnology Industries Ltd. (TASE: CBI) has signed a non-binding letter of intent to sell diabetes treatment developer Andromeda Biotech Ltd. to a US pharmaceutical company for an immediate More...

Gali Weinreb On Thursday, February 20th, 2014

Teva Sells Andromeda Diabetes Treatment Stake For $72 Million

– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1 Diabetes. – Clal Biotechnology Industries Ltd. (TASE: CBI) More...

Wordpress site Developed by Fixing WordPress Problems